Literature DB >> 8293422

Metallothionein in human lung carcinoma.

B A Hart1, G W Voss, P M Vacek.   

Abstract

Eleven pairs of surgically resected lung cancers and corresponding non-neoplastic lung tissue were evaluated for metallothionein (MT) and metal content (cadmium and copper) by the heme/109Cd binding assay and atomic absorption spectroscopy, respectively. Tissue samples, obtained from patients ranging in age from 51 to 79, included six adenocarcinomas, two small cell carcinomas, one mixed cell carcinoma, one squamous cell carcinoma, and one carcinoma of non-primary origin (i.e., melanoma). Paired t-tests showed that metallothionein and copper concentrations in lung tumor tissue were significantly elevated when compared to non-malignant lung tissue. Cu was the major metal associated with the 10 kDa MT fraction in lung tumors whereas Cd was the primary metal bound to MT from non-neoplastic lung tissue. Since Cu-thionein is also known to be elevated in fetal lung tissue, the possibility exists that MT might represent an oncodevelopmental product which is useful as a biomarker for the early detection of lung carcinoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8293422     DOI: 10.1016/0304-3835(93)90196-g

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  2 in total

1.  Heavy metal-induced metallothionein expression is regulated by specific protein phosphatase 2A complexes.

Authors:  Liping Chen; Lu Ma; Qing Bai; Xiaonian Zhu; Jinmiao Zhang; Qing Wei; Daochuan Li; Chen Gao; Jie Li; Zhengbao Zhang; Caixia Liu; Zhini He; Xiaowen Zeng; Aihua Zhang; Weidong Qu; Zhixiong Zhuang; Wen Chen; Yongmei Xiao
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

2.  Prognostic significance of metallothionein expression in renal cell carcinoma.

Authors:  Dionisios Mitropoulos; Aspasia Kyroudi-Voulgari; Stamatis Theocharis; Efraim Serafetinides; Epaminondas Moraitis; Anastasios Zervas; Christos Kittas
Journal:  World J Surg Oncol       Date:  2005-01-17       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.